Integrated theory to unify status among schizophrenia and manic depressive illness

Medical Hypotheses

Volumn 85, Issue 4, 2015, Pages 506-511

  Fukuda, K ^a  

^a Soka Clinic of Psychosomatic Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; ATYPICAL ANTIPSYCHOTIC AGENT; BRANCHED CHAIN AMINO ACID; DOPAMINE; KYNURENIC ACID; KYNURENINE; LEVODOPA; NITRIC OXIDE; PHENYLALANINE 4 MONOOXYGENASE; SEROTONIN; TETRAHYDROBIOPTERIN; TRYPTOPHAN; TRYPTOPHAN HYDROXYLASE; TYROSINE; TYROSINE 3 MONOOXYGENASE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BIOPTERIN; NEUROLEPTIC AGENT; SAPROPTERIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADRENERGIC SYSTEM; AMINO ACID TRANSPORT; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; CHAOS THEORY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; DRUG INDUCED DISEASE; EXCITATION; FIRING RATE; FUNERAL MANIA; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LETTER; LIFE STRESS; MANIA; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MOTOR DYSFUNCTION; NEGATIVE FEEDBACK; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PHYSICAL HYPERACTIVITY; PHYSICAL HYPOACTIVITY; PREMENSTRUAL SYNDROME; PSYCHOMOTOR EXCITATION; PUERPERAL DEPRESSION; SCHIZOPHRENIA; SEASONAL AFFECTIVE DISORDER; SEROTONIN SYNDROME; SIGNAL TRANSDUCTION; TRICYCLIC ANTIDEPRESSANT INDUCED MANIC SWITCHING; ANALOGS AND DERIVATIVES; DEPRESSION; FEMALE; HALLUCINATION; MALE; METABOLISM; PARANOID PSYCHOSIS; PATHOPHYSIOLOGY;

5-HYDROXYTRYPTOPHAN; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BIOPTERIN; BIPOLAR DISORDER; BLOOD-BRAIN BARRIER; DEPRESSION; DEPRESSION, POSTPARTUM; DOPAMINE; FEMALE; HALLUCINATIONS; HUMANS; KYNURENIC ACID; LEVODOPA; MALE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTRANSMITTER AGENTS; PARANOID DISORDERS; PREMENSTRUAL SYNDROME; SCHIZOPHRENIA; SEASONAL AFFECTIVE DISORDER; SEROTONIN; SEROTONIN SYNDROME; TYROSINE;

EID: 84942502463     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.06.012     Document Type: Letter

References (53)

1. Fukuda K. 5-HTP hypothesis of schizophrenia. Med Hypotheses 2013, 82:20-23.
2. Meyer T., Brinck U. Differential distribution of serotonin and tryptophan hydroxylase in the human gastrointestinal tract. Digestion 1999, 60:63-68.
3. Nakamura K., Sato T., Ohashi A., Tsurui H., Hasegawa H. Role of a serotonin precursor in development of gut microvilli. Am J Pathol 2008, 172:333-344.
4. Allen N.C., Bagade S., McQueen M.B., et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008, 40:827-834.
5. Saetre P., Lundmark P., Wang A., et al. The tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility, and suicidal behavior: a multi-centre case-control study and meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2010, 153B(2):387-396.
6. Zaboli G., Jönsson E.G., Gizatullin R., Asberg M., Leopardi R. Tryptophan hydroxylase-1 gene variants associated with schizophrenia. Biol Psychiatry 2006, 60:563-569.
7. Andre K., Kampman O., Vikki M., et al. TPH1 A218C polymorphism and temperament in major depression. BMC Psychiatry 2013, 13:118.
8. Arias B., Fabbri C., Gressier F., et al. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. Neuropsychobiology 2013, 67:41-47.
9. Chen D., Liu F., Yang C., et al. Association between the TPH1 A218C polymorphism and risk of mood disorders and alcohol dependence: evidence from the current studies. J Affect Disord 2012, 138:27-33.
10. Viikki M., Kampman O., Illi A., et al. TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response. Neurosci Lett 2010, 468:80-84.
11. Breier A., Adler C.M., Weisenfeld N., et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 1998, 29:142-147.
12. Erhardt S., Blennow K., Nordin C., Skogh E., Lindstrom L.H., Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001, 131:96-98.
13. Fukuda K. Etiological classification of depression based on the enzymes of tryptophan metabolism. BMC Psychiatry 2014, 14:372.
14. Blau N., Thöny B. Tetrahydrobiopterin in biomedical research. J Inherit Metab Dis 2009, 32:1-2.
15. Richardson M.A., Read L.L., Taylor Clelland C.L., et al. Evidence for a tetrahydrobiopterin deficit in schizophrenia. Neuropsychobiology 2005, 52:190-201.
16. Okusaga O., Muravitskaja O., Fuchs D., et al. Elevated levels of plasma phenylalanine in schizophrenia: a guanosine triphosphate cyclohydrolase-1 metabolic pathway abnormality?. PLoS One 2014, 9:e85945.
17. Hashimoto R., Ozaki N., Ohta T., Kasahara Y., Kaneda N., Nagatsu T. The plasma tetrahydrobiopterin levels in patients with affective disorders. Biol Psychiatry 1990, 28:526-528.
18. Meltzer H.Y., Umberkoman-Wiita B., Robertson A., Tricou B.J., Lowy M., Perline R. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. I. Enhanced response in depression and mania. Arch Gen Psychiatry 1984, 41:366-374.
19. Shiah I.S., Yatham L.N. Serotonin in mania and in the mechanism of action of mood stabilizers: a review of clinical studies. Bipolar Disord 2000, 2:77-92.
20. Fernstrom J.D. Branched-chain amino acids and brain function. J Nutr 2005, 135:1539-1546.
21. Craft L., Landers D. The effect of exercise on clinical depression and depression resulting from medical illness: a meta-analysis. J Sport Exerc Psychol 1998, 20:339-357.
22. Otto M.W., Church T.S., Craft L.L., Greer T.L., Smits J.A., Trivedi M.H. Exercise for mood and anxiety disorders. J Clin Psychiatry 2007, 68:669-676.
23. Hashiguti H., Nakahara D., Maruyama W., Naoi M., Ikeda T. Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis. J Neural Transm Gen Sect 1993, 93:213-223.
24. McInnes R.R., Kaufman S., Warsh J.J., et al. Biopterin synthesis defect. Treatment with L-dopa and 5-hydroxytryptophan compared with therapy with a tetrahydropterin. J Clin Invest 1984, 73:458-469.
25. Sumi-Ichinose C., Urano F., Kuroda R., et al. Catecholamines and serotonin are differently regulated by tetrahydrobiopterin: a study from 6-pyruvoyltetrahydropterin synthase knockout mice. J Biol Chem 2001, 276:41150-41160.
26. Lorenz E.N. Deterministic nonperiodic flow. J Atmos Sci 1963, 20:130-141.
27. Harsch H.H., Miller M., Young L.D. Induction of mania by L-dopa in a nonbipolar patient. J Clin Psychopharmacol 1985, 5:338-339.
28. Silverstone T. Dopamine in manic depressive illness: a pharmacological synthesis. J Affect Disord 1985, 8:225-231.
29. Scarna A., Gijsman H.J., McTavish S.F., Harmer C.J., Cowen P.J., Goodwin G.M. Effects of a branched-chain amino acid drink in mania. Br J Psychiatry 2003, 182:210-213.
30. Gurrera R.J. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999, 156:169-180.
31. Kamińska T., Szuster-Ciesielska A., Wysocka A., Marmurowska-Michałowska H., Dubas-Slemp H., Kandefer-Szerszeń M. Serum cytokine level and production of reactive oxygen species (ROS) by blood neutrophils from a schizophrenic patient with hypersensitivity to neuroleptics. Med Sci Monit 2003, 9:CS71-CS75.
32. Guillemin G.J., Smith D.G., Kerr S.J., et al. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Rep 2000, 5:108-111.
33. Guillemin G.J., Smythe G., Takikawa O., Brew B.J. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005, 49:15-23.
34. Nagatsu T., Ichinose H. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin. Mol Neurobiol 1999, 19:79-96.
35. Jendzjowsky N.G., Just T.P., Jones K.E., DeLorey D.S. Acute tetrahydrobiopterin supplementation attenuates sympathetic vasoconstrictor responsiveness in resting and contracting skeletal muscle of healthy rats. Physiol Rep 2014, 2:e12164.
36. Riddell D.R., Owen J.S. Nitric oxide and platelet aggregation. Vitam Horm 1999, 57:25-48.
37. Vásquez-Vivar J., Kalyanaraman B., Martásek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic Res. 2003, 37:121-127.
38. Mary K.K., Ian J.B. Tetrahydrobiopterin deficiency. Oxidative stress and free radical damage in neurology. Oxidative stress in applied basic research and clinical practice 2011, 225-234. Springer, New York. G. Natan, H.G. Hans (Eds.).
39. Deakin J.F.W., Graeff F.G. 5-HT and mechanisms of defence. J Psychopharmacol 1991, 5:305-315.
40. Farkas E., Jansen A.S., Loewy A.D. Periaqueductal gray matter input to cardio-related sympathetic premotor neurons. Brain Res 1998, 792:179-192.
41. Pearce R.K., Heikkilä M., Lindén I.B., Jenner P. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacolog (Berl) 2001, 156:402-409.
42. Boyer E.W., Shannon M. The serotonin syndrome. N Engl J Med 2005, 352:1112-1120.
43. Koszewska I., Rybakowski J.K. Antidepressant-induced mood conversions in bipolar disorder: a retrospective study of tricyclic versus non-tricyclic antidepressant drugs. Neuropsychobiology 2009, 59:12-16.
44. Cookson J.C. Triangulating views on antipsychotics. Adv Psychiatr Treat 2008, 14:17.
45. Leucht S., Davis J.M. Are all antipsychotic drugs the same?. Br J Psychiatry 2011, 199:269-271.
46. Cipriani A., Barbui C., Salanti G., et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011, 378:1306-1315.
47. Kim D.R., Czarkowski K.A., Epperson C.N. The relationship between bipolar disorder, seasonality, and premenstrual symptoms. Curr Psychiatry Rep 2011, 13:500-503.
48. Dias R.S., Lafer B., Russo C., et al. Longitudinal follow-up of bipolar disorder in women with premenstrual exacerbation: findings from STEP-BD. Am J Psychiatry 2011, 168:386-394.
49. Payne J.L., Roy P.S., Murphy-Eberenz K., et al. Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. J Affect Disord 2007, 99:221-229.
50. Munk-Olsen T., Laursen T.M., Mendelson T., Pedersen C.B., Mors O., Mortensen P.B. Risks and predictors of readmission for a mental disorder during the postpartum period. Arch Gen Psychiatry 2009, 66:189-195.
51. Johnson S.L., Cuellar A.K., Ruggero C., et al. Life events as predictors of mania and depression in bipolar I disorder. J Abnorm Psychol 2008, 117:268-277.
52. Mathew M.R., Chandrasekaran R., Sivakumar V. A study of life events in mania. J Affect Disord 1994, 32:157-161.
53. Correll C.U., Hauser M., Penzner J.B., et al. Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode. Bipolar Disord 2014, 16:478-492.